论文部分内容阅读
阿斯匹林除具有较强的解热镇痛和良好的抗风湿作用外,还对血小板聚集有特异的抑制作用。它对血小板的环氧酶有不可逆的乙酰化作用,阻断了血栓素(TXA_2)的合成,故而有抑制血小板的聚集作用。长期服用<20mg/d本品,可抑制TXA_2达90％以上;服用大剂量肯定能抑制血小板的聚集作用。在20～40mg/d它能明显地减少抑制血小板的二十烷酸类(eicosenoid)和前列环素(Prostac-yclin),证明小剂量本品有生化选择性。现已证明本品有防止血管栓塞的发生及复发的作用。用7种安慰剂,15000多名患者进行防止Ⅱ期心肌梗塞试验取得成功,其剂量为300～1500mg/d。在死亡率方面,每单一试验并无统计学意义,但将结果汇集起来看,本品具有良好效果。据
Aspirin in addition to a strong antipyretic analgesic and good anti-rheumatic effects, but also on platelet aggregation has a specific inhibitory effect. It has irreversible acetylation of platelet cyclooxygenase, blocking the synthesis of thromboxane (TXA_2), and thus inhibiting the aggregation of platelets. Long-term use of <20mg / d of this product can inhibit TXA_2 up to 90%; taking large doses will certainly inhibit platelet aggregation. At 20-40 mg / d, it significantly reduces platelet-inhibiting eicosenoids and prostacyclin (Prostac-yclin), demonstrating the biochemical selectivity of this product at low doses. It has been proved that this product has to prevent the occurrence and recurrence of vascular embolism. With seven placebo, more than 15,000 patients to prevent Ⅱ myocardial infarction success, the dose of 300 ~ 1500mg / d. In terms of mortality, there is no statistical significance for each single test, but the results are pooled together and the product has good effect. according to